SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
北北
Lv1
10 积分
2021-06-04 加入
最近求助
最近应助
互助留言
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
5天前
已完结
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
5天前
已完结
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
5天前
已完结
Global health 2050: the path to halving premature death by mid-century
5天前
已关闭
Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio
6天前
已完结
Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report
9天前
已完结
Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/CTLA-4 Bi-specific antibody): a case report
9天前
已完结
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
12天前
已完结
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
15天前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
没有进行任何应助
感谢
5天前
感谢
5天前
感谢
5天前
没找到【积分已退回】
5天前
感谢
6天前
感谢
9天前
感谢
9天前
感谢
12天前
感谢
15天前
感谢
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论